Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology
+$0.48 today
- Market cap
- $2.17B
- Beta
- 2.20
- P/E (TTM)
- -52.3
- EPS (TTM)
- -$0.63
Volume 4.86M
Average 2.11M
BEAM Long-term Debt
Borrowings due after more than one year.
Beam Therapeutics Inc.NASDAQ: BEAM
Long-term Debt · Q2 FY2026 · quarter ended Jun 2026
Long-term debt remains negative
Q2 FY2026 long-term debt was $100.26M, compared with $0 a year earlier.
Context
- Long-term debt amounted to 7.2% of total assets at the end of Q2 FY2026, up 7.2 pp from a year earlier.
- Long-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 139.76M USD
- Year-over-year change
- —
- 4-year CAGR
- +161.1%
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 139.76M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 3.01M | — |
Long-term Debt vs competitors
How BEAM compares with its peers on the latest reported figures
- BEAM's Jun 2026 long-term debt of $100.26M is the 2nd highest of the 9 companies compared; the peer median is $54.29M.
- Long-term debt amounts to 7.2% of total assets for BEAM, versus a peer median of 19.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $761.15M | +294.9% | — | 29.8% | |
| Jun 2026 | $100.26M | — | — | 7.2% | |
| Mar 2026 | $72.05M | — | — | 25.3% | |
| Mar 2026 | $67.5M | +47.6% | +76.0% | 23.3% | |
| Mar 2026 | $61.4M | — | — | 8.1% | |
| Mar 2026 | $47.18M | — | — | 31.6% | |
| Mar 2026 | $22.42M | +0.4% | +0.3% | 15.6% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BEAM) | $54.29M | +47.6% | +38.2% | 19.5% | |
Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 559.99M | 232.77M | 435.9M | 281.97M | 294.94M |
| Short-term Investments | 405.65M | 845.37M | 753.98M | 568.77M | 950.27M |
| Net Receivables | 300M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 14.76M | 21.17M | 27.41M | 0 |
| Total Current Assets | 1.27B | 1.09B | 1.21B | 878.15M | 1.27B |
| Property, Plant & Equipment (Net) | 186.98M | 234.13M | 237.81M | 216.28M | 205.18M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 6.68M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 14.47M | 14.69M | 10.87M | 9.4M | 634K |
| Total Non-current Assets | 201.45M | 248.82M | 248.67M | 225.68M | 212.49M |
| Total Assets | 1.47B | 1.34B | 1.46B | 1.1B | 1.48B |
| Account Payables | 7.47M | 9.03M | 1.62M | 3.87M | 10.23M |
| Short-term Debt | 2.29M | 0 | 0 | 0 | 14.36M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 86.27M | 135.97M | 68.71M | 108.86M | 6.66M |
| Other Current Liabilities | 60.83M | 49.68M | 100.69M | 19.74M | 36.34M |
| Total Current Liabilities | 213.44M | 223.6M | 205.57M | 182.07M | 96.94M |
| Long-term Debt | 3.01M | 0 | 0 | 0 | 139.76M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 262.3M | 202.18M | 109.89M | 33.22M | 0 |
| Other Non-current Liabilities | 34.16M | 13.84M | 3.02M | 7.04M | (133.63M) |
| Total Non-current Liabilities | 434.28M | 384.65M | 272.82M | 188.21M | 145.88M |
| Total Liabilities | 647.72M | 608.24M | 478.39M | 370.28M | 242.82M |
| Common Stock | 684K | 712K | 816K | 836K | 1.02M |
| Retained Earnings | (768.27M) | (1.06B) | (1.19B) | (1.57B) | (1.64B) |
| Accumulated OCI | (50K) | (2.43M) | 604K | 679K | 1.11M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 826.74M | 733.47M | 981.33M | 733.55M | 1.24B |
| Total Debt | 147.64M | 179.01M | 172.69M | 161.43M | 293.88M |
| Net Debt | (412.35M) | (53.76M) | (263.21M) | (120.54M) | (1.06M) |
Beam Therapeutics Inc.
NASDAQ:BEAM
Intrinsic Alpha fair value
Locked
Current Price
$21.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.